Merck $MRK and Google $GOOGL Cloud announced a multi-year partnership valued at up to $1 billion to deploy an AI agent platform across the drugmaker's operations, the companies said April 22 at Google's Cloud Next conference in Las Vegas.
Under the agreement, Google Cloud engineers will be embedded with Merck's teams, and the company will gain access to the Gemini Enterprise platform, with the work spanning R&D, manufacturing, commercial, and corporate functions, the companies said.
Although no fixed end date has been set, Williams told Reuters he expects the relationship to last at least ten years. "I easily see us investing a billion over the next several years in this, in those capabilities," he said. "We're not just buying tokens. It is really the tool set" Google Cloud offers, he added.
On the practical side, Williams pointed to AI-assisted preparation of clinical study reports — an effort roughly two years in the making — as well as plans to simulate lab experiments digitally and streamline regulatory submissions. Separately, Google's tools have already halved both the time and expense involved in assembling country-specific reimbursement dossiers, he said, and that work is being rolled out worldwide.
Williams was direct about the maturity of the effort. "This isn't a pilot," he told Reuters. "We're submitting dossiers in markets using this new capability."
Thomas Kurian, CEO of Google Cloud, a unit of Alphabet, described the collaboration as "a fundamental shift in how technology supports the entire pharma value chain." In a statement, Kurian said the partnership is "building a future where the speed of AI and the expertise of human ingenuity come together to bring drugs to patients faster."
Merck said the platform will also support data-driven personalization in commercial and patient engagement, as well as AI-powered automation in corporate functions to boost productivity across the company's roughly 75,000 employees worldwide.
Williams said in a statement that the partnership marks "the next phase of our AI journey" as Merck enters "one of the most significant launch periods in our company's history."